Latest Regulatory Risk News

Mayne Pharma has announced the expiration of the US antitrust waiting period, a critical step forward in Cosette Pharmaceuticals' proposed acquisition. The transaction now moves closer to completion, pending other regulatory and shareholder approvals.

Spenda Limited has responded to an ASX price query following a notable rise in its share price and trading volume, denying any undisclosed material information while confirming ongoing confidential negotiations for virtual card and funding services.

Westpac Banking Corporation reported a modest 1% decline in net profit to AUD 3.317 billion for the six months ended March 2025, maintaining its interim dividend and advancing key digital and sustainability initiatives.

VDM Group Limited faces suspension on the ASX due to a joint venture dispute in Angola, halting exploration activities. The company is pivoting towards new critical minerals projects in Australia to restore trading and investor confidence.

St Barbara Limited confirms a robust Simberi Expansion Project with a 13-year life of mine plan delivering 2.2 million ounces of gold and annual production exceeding 220,000 ounces from FY28. The project’s strong economics and infrastructure upgrades position it as a significant growth driver amid regulatory uncertainties.

St Barbara Limited reports a strong quarter with Simberi gold production up 37% and a robust US$235 million expansion plan, while navigating a critical tax assessment review in Papua New Guinea.

Emyria Limited reports sustained clinical success in its PTSD program, launches a new treatment-resistant depression therapy, and opens a second Empax Centre to meet growing demand. The company is progressing funding discussions with health insurers and government bodies to support expansion.

Donaco International reported a modest revenue and EBITDA decline in Q3 FY2025 but strengthened its cash reserves. Meanwhile, the company agreed to a full acquisition scheme at a significant premium, setting the stage for shareholder decisions amid regulatory uncertainties.

St Barbara’s Simberi Gold has formally objected to Papua New Guinea’s tax authority over a disputed PGK456 million assessment, highlighting significant errors and seeking urgent resolution.

Infini Resources Limited has announced a $3.4 million capital raise through a flow-through share offer aimed at advancing exploration at its Portland Creek Uranium Project in Canada. The prospectus highlights significant risks but underscores the company's strategic focus on critical minerals.

BMG Resources has addressed ASX's query on recent share price and volume spikes, confirming no undisclosed information but highlighting imminent assay results from its Abercromby Gold Project.

Argenica Therapeutics reported a 16% reduction in half-year losses to $1.19 million, buoyed by a 29% increase in other income largely from R&D tax incentives, as it advances its neuroprotective drug development.